Brief: Argent Biopharma To Acquire Core Operating Assets And IP Portfolio Of Auscann Group
19/08/2025 02:36
Aug 19 (Reuters) - Argent BioPharma Ltd RGT.AX: BINDING TERM SHEET TO ACQUIRE CORE OPERATING ASSETS AND IP PORTFOLIO OF AUSCANN GROUP HOLDINGS WILL ISSUE AC8 25 MILLION ORDINARY SHARES, VALUED AT USD 15 MILLION Further company coverage: RGT.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Argent BioPharma
See all newsBrief: Argent Biopharma Executes Global Licence For Non-Core Cannabis Genetics
Brief: Argent Biopharma Files Provisional US Patent On Immune Modulation And Longevity
Australia's Argent BioPharma rises to over 1-month high on new licence agreement
Brief: Argent Biopharma Signs NLC Licence To Expand Antiviral Portfolio
Brief: Argent Biopharma Says FDA-CVM Established Inad File For Cannepil Veterinary Program